BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28532609)

  • 1. Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Lai TY; Wang TH; Liu CJ; Chao TF; Chen TJ; Hu YW
    Radiother Oncol; 2017 Jun; 123(3):406-411. PubMed ID: 28532609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
    Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
    J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of predisposing factors for osteonecrosis of the jaw after marginal mandibulectomy in the surgical management of oral squamous cell carcinoma.
    Ito R; Huang JJ; Hsieh WC; Kao HK; Lao WW; Fang KH; Huang Y; Chang YL; Cheng MH; Chang KP
    J Surg Oncol; 2018 Mar; 117(4):781-787. PubMed ID: 29165823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
    BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive predictive value of the International Classification of Diseases, 10th revision, codes to identify osteonecrosis of the jaw in patients with cancer.
    Gammelager H; Erichsen R; Antonsen S; Nørholt SE; Neumann-Jensen B; Ehrenstein V; Acquavella J; Sørensen HT
    Cancer Epidemiol; 2012 Aug; 36(4):381-3. PubMed ID: 22534488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
    de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study.
    Huang YF; Muo CH; Tsai CH; Liu SP; Chang CT
    Clin Oral Investig; 2019 Feb; 23(2):585-593. PubMed ID: 29725850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental extraction: a population-based cohort study.
    Huang YF; Chang CT; Muo CH; Tsai CH; Shen YF; Wu CZ
    PLoS One; 2015; 10(4):e0120756. PubMed ID: 25880208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
    Lee CY; Suzuki JB
    Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw: who gets it, and why?
    Reid IR
    Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy.
    Fleisher KE; Jolly A; Venkata UD; Norman RG; Saxena D; Glickman RS
    J Oral Maxillofac Surg; 2013 Mar; 71(3):513-9. PubMed ID: 22999296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.